PUBLICATION
India Pharmaceuticals 2017
India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs globally and a proponent of high-quality affordable medicines. The industry has posted double-digit growth over the last few years, rising to US$36.7 billion and projected to grow to US$40 billion by 2020. However, as price erosion continues to impact the market and competition increases, many of India’s pharmaceutical companies will be hard-pressed to continue pushing products into the market at ever-more affordable prices. A number of policies under discussion, outlined in the Draft Pharmaceutical Policy 2017, seek to address the challenges faced by Indian pharmaceutical companies. Implementation and open dialogue between government and industry will be key in ensuring its success.
RELATED INTERVIEWS MORE INTERVIEWS
RELATED ARTICLES MORE ARTICLES
Raising the bar: India’s generic players compete for market share
Building Blocks: Bulk Drugs, Excipients and Intermediates
RECENT PUBLICATIONS
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
